- Home
- TH vs NUVB Comparison
TH vs NUVB Comparison
Compare TH & NUVB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TH
- NUVB
- Stock Information
- Founded
- TH 1978
- NUVB 2018
- Country
- TH United States
- NUVB United States
- Employees
- TH N/A
- NUVB N/A
- Industry
- TH Hotels/Resorts
- NUVB Biotechnology: Pharmaceutical Preparations
- Sector
- TH Consumer Discretionary
- NUVB Health Care
- Exchange
- TH Nasdaq
- NUVB Nasdaq
- Market Cap
- TH 932.0M
- NUVB 959.2M
- IPO Year
- TH N/A
- NUVB N/A
- Fundamental
- Price
- TH $10.65
- NUVB $2.51
- Analyst Decision
- TH Hold
- NUVB Strong Buy
- Analyst Count
- TH 3
- NUVB 6
- Target Price
- TH $11.50
- NUVB $7.00
- AVG Volume (30 Days)
- TH 440.5K
- NUVB 3.0M
- Earning Date
- TH 03-12-2025
- NUVB 02-27-2025
- Dividend Yield
- TH N/A
- NUVB N/A
- EPS Growth
- TH N/A
- NUVB N/A
- EPS
- TH 0.87
- NUVB N/A
- Revenue
- TH $428,804,000.00
- NUVB $2,162,000.00
- Revenue This Year
- TH N/A
- NUVB N/A
- Revenue Next Year
- TH N/A
- NUVB $369.72
- P/E Ratio
- TH $12.17
- NUVB N/A
- Revenue Growth
- TH N/A
- NUVB N/A
- 52 Week Low
- TH $6.11
- NUVB $1.44
- 52 Week High
- TH $11.84
- NUVB $4.16
- Technical
- Relative Strength Index (RSI)
- TH 69.11
- NUVB 42.25
- Support Level
- TH $9.35
- NUVB $2.44
- Resistance Level
- TH $11.10
- NUVB $2.77
- Average True Range (ATR)
- TH 0.39
- NUVB 0.23
- MACD
- TH 0.09
- NUVB -0.04
- Stochastic Oscillator
- TH 74.24
- NUVB 6.40
About TH Target Hospitality Corp.
Target Hospitality Corp is a vertically integrated specialty rental and hospitality services company in the United States. The company provides vertically integrated specialty rental and comprehensive hospitality services including catering food services, maintenance, housekeeping, grounds-keeping, on-site security, overall workforce lodge management, and laundry service. Its operating segment includes HFS-South and HFS-Midwest; Government; TCPL Keystone and others. It generates a majority of its revenue from the Government segment which consists of specialty rental and vertically integrated hospitality services revenue from customers with Government contracts located in Texas.
About NUVB Nuvation Bio Inc.
Nuvation Bio Inc is a biopharmaceutical company tackling unmet needs in oncology by developing differentiated and novel therapeutic candidates. The company's clinical-stage product candidate is NUV-868, a BD2-selective oral small molecule BET inhibitor. NUV-868 inhibits the protein BRD4, a key member of the BET family that epigenetically regulates a number of important proteins that control tumor growth and differentiation, including oncogenes such as c-myc. Notably, BET proteins have critical biological functions and are found to be altered in many human cancers. It is also developing its proprietary, small molecule Drug-Drug Conjugate (DDC) platform, a novel therapeutic approach within the drug-conjugate class of anti-cancer therapies with parallels to Antibody-Drug Conjugates (ADCs).